Sage Therapeutics and Biogen have delivered a clear win for zuranolone in the phase 3 SKYLARK trial of women with postpartum depression (PPD), although questions about the commercial opportunity led to a muted response to the data.
Analysts surveyed by Evaluate Pharma predict AbbVie will generate more prescription drug sales than any company in 2028. They see AbbVie's $66 billion in expected 2028 sales closely followed by Roche at $65 billion. Johnson & Johnson, Merck and Pfizer round out the top 5 in their projections.
Insurers can expect a stable credit outlook and low double-digit earnings growth this year after a strong first quarter, according to a forecast from Moody's Investors Service.
BioMarin’s commercial aspirations for its hemophilia gene therapy remain on ice after the FDA lobbed additional questions for the company to address, pushing back an expected approval submission to September.
Two months after launching her new rural healthcare startup Homeward, former Livongo executive Jennifer Schneider, M.D., has landed a big partnership with retail pharmacy Rite Aid.
The FDA has rescinded its accelerated approval of TG Therapeutics' lymphoma drug Ukoniq because of concerns that its use might increase the risk of death. The risk became apparent during a phase 3 trial of the drug in chronic lymphocytic lymphoma (CLL) and small lymphocytic lymphoma (SLL) patients.
SCWorx agreed to a settlement with the SEC that will see it pay a $125,000 penalty and a disgorgement of $471,000, plus prejudgment interest of just over $32,700.
Hospitals and health systems in April saw their median operating margins decline by nearly 40% compared to March as lower volumes and higher expenses take a toll.
Back in 2020, Amgen cast aside a cardiovascular disease hopeful from Cytokinetics and pointed the spotlight at a small interfering RNA treatment it thought could make up for the lost partnership. Now, in some limited phase 2 data, the pharma is making its case.
Sanofi is aiming to switch erectile dysfunction pill Cialis from prescription to over-the-counter availability, but the FDA isn't allowing the trial to continue for now.
